| Literature DB >> 35812371 |
Hao-Su Zhan1,2,3,4, Xin Yao1, Hai-Yi Hu1, Yan-Fei Han5, Bing Yue6, Li-Ying Sun2,3,4, Yong-Jun Wang1.
Abstract
Background: Autoimmune gastritis (AIG) and Primary Sjögren's syndrome (pSS) are both autoimmune diseases with low prevalence in China. Subacute combined degeneration (SCD) of the spinal cord is the most common neurological manifestation of vitamin B12 deficiency. Until now, a patient with pSS and complications of AIG including SCD has not been reported. Case Presentation: A 69-year-old woman presented with palpitations and symmetrical and progressive numbness in her hands and feet. The patient had a sense of stepping on cotton and could not write or walk without help. We reviewed the patient's history and analyzed her blood tests, imaging, gastroscopic findings, and pathological results. The patient fulfilled the criteria of AIG, pSS, spinal cord SCD and early pernicious anemia (PA) simultaneously. Although pSS can lead to reduction of vitamin B12, this is the first overlapping case of pSS with spinal cord SCD. After symptomatic treatment, the patient returned to a normal life. Conclusions: This first report about the coexistence of pSS and complications of AIG including SCD and PA will promote a better understanding of the relationship between these diseases.Entities:
Keywords: autoimmune gastritis; case report; pernicious anemia; primary Sjögren’s syndrome; subacute combined degeneration of the spinal cord
Mesh:
Year: 2022 PMID: 35812371 PMCID: PMC9260500 DOI: 10.3389/fimmu.2022.908528
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 8.786
Figure 1Magnetic resonance image (MRI) findings in the spinal cord. (A) abnormal longitudinally extensive T2 weighted hyperintensities involving the posterior columns (the red arrow) (B) inverted V or “rabbit ears” sign on cervical spinal (the red arrow). (C) abnormal hyperintensities involving the posterior columns disappeared in MRI after treament. (D) recovered MRI image on cervical spinal after treament.
Laboratory test results before and after treatment.
| Items | Measured value | Reference range | |
|---|---|---|---|
| Before treatment | After treatment | ||
| RBC (×1012/L) | 3.33 | 4.07 | 3.5-5 |
| Hb (g/L) | 129 | 125 | 110-150 |
| MCV (fL) | 110.2 | 92.60 | 82-95 |
| MCH (pg) | 38.7 | 30.70 | 27-31 |
| MCHC (g/L) | 351 | 332 | 320-360 |
| RBC volume distribution width (fl) | 54.0 | 39.80 | 39.0-46.0 |
| Platelet (×109/L) | 388 | 231 | 100-350 |
| Thrombocytocrit (%) | 0.31 | 0.23 | 0.10-0.28 |
| WBC (×109/L) | 5.83 | 4.14 | 4-10 |
| Vitamin B12 (pg/ml) | 74.00 | Medication | 180-914 |
| Folic acid (ng/ml) | >23.90 | Medication | 3.1-19.9 |
| ESR (mm/h) | 37 | 17 | 0-20 |
| Homocysteine (μmol/L) | 124.1 | 11.0 | 0-20 |
| GGT (U/L) | 55 | 24 | 7-45 |
| A/G | 1.49 | 1.72 | 1.5-2.5 |
| Intrinsic factor antibody (Au/ml) | Positive (8.92) | Negative | |
| Parietal cell antibody | +1:80 | +1:80 | Negative |
| ANA | +1:320 | +1:160 | Negative |
| Anti CENP B antibody | +++ | ++ | Negative |
| Anti SSA60 | + | Negative | Negative |
| CCP | Negative | Negative | |
| RF | Negative | Negative | Negative |
| MTHFR | Mutant type (TT) | Negative | |
| CYFRA21-1 (ng/ml) | 3.47 | 3.84 | 0.1-3.3 |
| CA72-4 (U/ml) | 127.00 | 18.10 | 0-6.9 |
| Alpha-fetoprotein (ng/ml) | 13.70 (0.01-7) | 10.08 (0.00-15) | In parentheses |
| C13 breath test | Negative | Negative | Negative |
| γ-globulin (%) | 14.6 | NA | 9.1-24.0 |
| β2-microglobulin (%) | 6.3 | NA | 1.8-6.2 |
| α1-globulin (%) | 5.2 | NA | 2.2-4.8 |
RBC, red-cell count; Hb, hemoglobin; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpusular hemoglobin concerntration; WBC, white blood cell; ESR, erythrocyte sedimentation rate; GGT, gamma-glutamyl transferase; ANA, anti-nuclear antibody; CCP, anti-cyclic citrullinated peptide antibody; RF, rheumatoid factors; MTHFR, Methylene tetrahydrofolate reductase; CA72-4, Cancer antigen CA72-4; NA, not available.
+ refers to a lighter degree, +++ refers to a heavier degree, and ++ refers to a degree between the two.
Figure 2Gastroscope shows the atrophic gastritis in fundus (A) and corpus(B), superficial gastritis in autrum (C) and a gastric polyp (arrow) in the corpus (D).
Figure 3Histopathology of gastric mucosa and labial salivary gland. (A) Hematoxylin and eosin staining (40×) displays a hyperplastic polyp in the corpus. (B) Hematoxylin and eosin staining (100×) displays the background of the hyperplastic polyp: atrophy, intestinal metaplasia and pseudo-pyloric adenylation in the mucosa. (C)Immunohistochemical staining of gastrin is negative in pseudo-pyloric gland. (D) Staining with anti-chromogranin antibodies (CgA) (100×) depicts dark brown endocrine cells (arrow). (E) Hematoxylin and eosin staining (100×) displays no obvious atrophy in the acinus of the labial salivary gland, but small and numerous foci of lymphocytic aggregation was observed (arrow). (F) The arrow indicates the squeeze of the lymphocytes.